gadobenate dimeglumine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 4471 127000-20-8

Description:

MoleculeDescription

Synonyms:

  • multihance
  • gadobenate dimeglumine
  • Molecular weight: 1058.16
  • Formula: C36H62GdN5O21
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 23, 2004 FDA BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 551.25 54.28 120 4956 4647 53339343
Hypersensitivity 380.75 54.28 240 4836 210425 53133565
Contrast media reaction 290.80 54.28 55 5021 1028 53342962
Urticaria 288.59 54.28 172 4904 135713 53208277
Skin hypertrophy 252.40 54.28 59 5017 3140 53340850
Anaphylactic reaction 234.24 54.28 113 4963 58213 53285777
Skin induration 222.20 54.28 53 5023 3077 53340913
Skin tightness 198.78 54.28 51 5025 4000 53339990
Anaphylactoid reaction 197.98 54.28 50 5026 3681 53340309
Sneezing 174.96 54.28 62 5014 14610 53329380
Pruritus 154.16 54.28 163 4913 293669 53050321
Vomiting 145.43 54.28 205 4871 496934 52847056
Skin fibrosis 138.87 54.28 29 5047 910 53343080
Erythema 137.74 54.28 116 4960 156853 53187137
Fibrosis 123.82 54.28 35 5041 3957 53340033
Nausea 117.81 54.28 235 4841 755856 52588134
Throat tightness 88.83 54.28 43 5033 22173 53321817
Throat irritation 85.30 54.28 47 5029 31634 53312356
Feeling hot 83.60 54.28 51 5025 41493 53302497
Skin hyperpigmentation 75.35 54.28 26 5050 5646 53338344
Dyspnoea 73.15 54.28 167 4909 586065 52757925
Joint range of motion decreased 72.51 54.28 35 5041 17921 53326069
Gadolinium deposition disease 72.40 54.28 11 5065 48 53343942
Joint contracture 70.85 54.28 19 5057 1765 53342225
Scar 67.66 54.28 30 5046 12663 53331327
Peau d'orange 67.34 54.28 12 5064 158 53343832
Anaphylactic shock 65.94 54.28 35 5041 21858 53322132
Emotional distress 65.83 54.28 40 5036 32277 53311713
Contrast media allergy 63.66 54.28 18 5058 2034 53341956
Foaming at mouth 63.12 54.28 16 5060 1192 53342798
Anhedonia 56.13 54.28 25 5051 10662 53333328
Skin discolouration 55.35 54.28 37 5039 35155 53308835

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 379.27 63.81 87 3028 4265 32506146
Hypersensitivity 291.63 63.81 131 2984 57627 32452784
Urticaria 173.43 63.81 93 3022 59521 32450890
Vomiting 169.11 63.81 155 2960 235402 32275009
Anaphylactic reaction 163.16 63.81 72 3043 30100 32480311
Skin induration 159.36 63.81 38 3077 2190 32508221
Skin hypertrophy 158.41 63.81 39 3076 2572 32507839
Sneezing 158.08 63.81 44 3071 4687 32505724
Nausea 156.44 63.81 171 2944 320678 32189733
Anaphylactoid reaction 147.76 63.81 36 3079 2272 32508139
Skin tightness 146.17 63.81 35 3080 2052 32508359
Contrast media reaction 140.63 63.81 29 3086 850 32509561
Joint contracture 107.68 63.81 27 3088 1916 32508495
Joint range of motion decreased 96.42 63.81 32 3083 6150 32504261
Fibrosis 95.63 63.81 26 3089 2531 32507880
Skin fibrosis 90.86 63.81 21 3094 1053 32509358
Scar 85.93 63.81 29 3086 5864 32504547
Pruritus 80.79 63.81 79 3036 128623 32381788
Anaphylactic shock 78.29 63.81 35 3080 14999 32495412
Extremity contracture 74.83 63.81 17 3098 789 32509622
Deformity 72.81 63.81 19 3096 1579 32508832

Pharmacologic Action:

SourceCodeDescription
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4032768 VUID
N0000188993 NUI
4032768 VANDF
CHEMBL1200571 ChEMBL_ID
C064572 MESH_SUPPLEMENTAL_RECORD_UI
3Q6PPC19PO UNII
24838350 PUBCHEM_CID
68173 RXNORM
19178 MMSL
64278 MMSL
64293 MMSL
d05428 MMSL
007717 NDDF
414308003 SNOMEDCT_US
C0209453 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MultiHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-5164 INJECTION, SOLUTION 529 mg INTRAVENOUS NDA 28 sections
MultiHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-5264 INJECTION, SOLUTION 529 mg INTRAVENOUS NDA 27 sections